SPORE IN BREAST CANCER

乳腺癌孢子将大大加强和扩大UAB综合癌症中心的乳腺癌研究，重点是转化研究。它的化学预防，基因治疗，靶向免疫治疗，抗血管生成，肿瘤发生的遗传机制和他莫昔芬耐药机制的主题都是国家优先领域。六个研究项目涉及跨学科的研究团队，包括：1）“新型维甲酸的临床前/临床开发”提供UAB设计的试剂的药物化学，临床前毒理学/功效和早期临床研究; 2）“激素抵抗：机制和抵抗”探索诱导他莫昔芬抵抗的机制和抗血管生成剂在逆转这一过程中的作用; 3）“新乳癌癌基因GKLF的生物学及中间标记作用”将探讨GKLF过度表达所导致的致癌机制，以及其作为化学预防试验中的中间标记的潜力; 4）“肿瘤血管特异性基因治疗”将开发靶向乳腺癌血管的新型腺病毒载体，作为抗肿瘤药物的介导剂。“乳腺癌的多核苷酸疫苗疗法”将设计方法以增强肿瘤抗原DNA疫苗在动物模型和患者中诱导抗肿瘤免疫力;以及6）“转移性乳腺癌的预靶向放射免疫疗法”，其将利用由单链抗体和链霉亲和素组成的新型融合蛋白将生物素-DOTA-放射性同位素定位于肿瘤部位。在动物模型和病人身上。这些项目将由三个核心支持：1）行政/生物统计学; 2）组织资源和免疫病理学; 3）临床试验。此外，SPORE将有一个针对乳腺癌转化研究职业的职业发展计划（5个奖项）和一个发展研究计划（每年5-6个试点项目）。该孢子有强大的机构承诺和热情的计划与其他孢子互动，包括我们自己的卵巢癌孢子。这个SPORE将增加科学发现，并迅速将资金转化为创新的临床试验。

The Breast Cancer SPORE will greatly strengthen and expand the breast cancer research of the UAB Comprehensive Cancer Center with an emphasis on translational research. It's themes of Chemoprevention, Gene Therapy, Targeted Immunotherapy, Anti-angiogenesis, Genetic Mechanisms of Oncogenesis, and Mechanisms of Tamoxifen Resistance are all national priority areas. Six research projects involve interdisciplinary investigative teams including: 1) "Preclinical/Clinical Development of Novel Retinoids" provides medicinal chemistry, preclinical toxicology/efficacy and early clinical study of UAB designed reagents; 2) "Hormonal Resistance: Mechanisms and Reversal" explores the mechanisms which induce Tamoxifen resistance and the role of anti- angiogenesis agents in reversal of this process; 3) "Biology and Intermediate Marker Role of a Novel Breast Cancer Oncogene, GKLF" will explore the oncogenic mechanisms resulting from GKLF over- expression and its potential as an intermediate marker in chemoprevention trials; 4) "Gene Therapy Specifically Directed at Tumor Vasculature" will develop novel adenoviral vectors targeted to breast cancer vasculature as mediators of anti-angiogenesis strategies; 5) Polynucleotide Vaccine Therapy of Breast Cancer" will design methods to enhance tumor antigen DNA vaccine induction of anti-tumor immunity in animal models and patients; and 6) "Pre-targeting Radioimmunotherapy of Metastatic Breast Cancer" which will utilize a novel fusion protein composed of single chain antibodies and streptavidin to localize Biotin-DOTA-radioactive isotopes to tumor sites. in animal models and patients. These projects will be supported by three Cores: 1) Administrative/Biostatistics; 2) Tissue Resource and Immunopathology; and 3) Clinical Trials. In addition, the SPORE will have a Career Development Program directed at careers in Breast Cancer Translational Research (5 awards) and a Developmental Research Program (5-6 pilot projects annually). The SPORE has strong institutional commitments and enthusiastic plans for interaction with other SPOREs including our own Ovarian Cancer SPORE. This SPORE will increase scientific discoveries and rapidly translate fundings into innovative clinical trials.